Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung J. | - |
dc.contributor.author | Choi Y.S. | - |
dc.contributor.author | Lee J.H. | - |
dc.contributor.author | Lee W.S. | - |
dc.contributor.author | Kim S.-H. | - |
dc.contributor.author | Park Y. | - |
dc.contributor.author | Lee S.-S. | - |
dc.contributor.author | Do Y.R. | - |
dc.contributor.author | Jo J.-C. | - |
dc.contributor.author | Lee J.-J. | - |
dc.contributor.author | Kim J.S. | - |
dc.contributor.author | Shin H.-J. | - |
dc.contributor.author | Shin D.-Y. | - |
dc.contributor.author | Yoon S.-S. | - |
dc.contributor.author | Min C.-K. | - |
dc.contributor.author | Kim K. | - |
dc.contributor.author | Eom H.-S. | - |
dc.contributor.author | The Korean Multiple Myeloma Working Party (KMMWP) | - |
dc.date.available | 2020-07-02T00:36:45Z | - |
dc.date.created | 2020-06-03 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/60118 | - |
dc.description.abstract | Autologous stem cell transplantation (ASCT) is not frequently performed for elderly patients multiple myeloma (MM) in Korea, despite its being a standardized approach for young patients. Medical records of 150 patients from 15 Korean institutions who received ASCT at age ≥ 64 years were analyzed retrospectively. Patients included had symptomatic MM, and had received their first ASCT at age ≥ 64 following induction chemotherapy. The main outcome was the response after ASCT. Overall survival (OS) and progression-free survival (PFS) were also analyzed. Median time to ASCT was 6.3 months. Complete response plus stringent complete response rate increased from 36 (24.0%) to 105 (70.0%) after ASCT, and high-quality response (≥ very good partial response) increased from 96 (64.0%) to 125 (83.3%). With a median follow-up of 32.6 months after ASCT, 5-year OS and PFS were 59.7% and 22.8%, respectively. Febrile neutropenia occurred in 43.5%, and nausea (21.3%) and stomatitis (13.2%) were common grade 3–4 non-hematologic adverse events. Of 44 deaths, disease progression (n = 23) was the most common cause of mortality, followed by infection (n = 13). Treatment-related death occurred in four cases (2.7%). ASCT is an effective and safe option for elderly MM patients and is associated with superior clinical outcomes. © 2020, Japanese Society of Hematology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | International Journal of Hematology | - |
dc.title | Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000535147900001 | - |
dc.identifier.doi | 10.1007/s12185-020-02869-y | - |
dc.identifier.bibliographicCitation | International Journal of Hematology | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85085288366 | - |
dc.citation.title | International Journal of Hematology | - |
dc.contributor.affiliatedAuthor | Lee J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Autologous | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Stem cell | - |
dc.subject.keywordAuthor | Transplantation | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.